• OPEN AN ACCOUNT
Indian Indices
Nifty
22,326.90 203.25
(0.92%)
Sensex
73,651.35 655.04
( 0.90%)
Bank Nifty
47,124.60 338.65
( 0.72%)
Nifty IT
34,898.15 153.80
( 0.44%)
Global Indices
Nasdaq
16,399.52 83.82
(0.51%)
Dow Jones
39,760.08 477.75
(1.22%)
Hang Seng
16,541.42 148.58
(0.91%)
Nikkei 225
40,168.07 -594.66
(-1.46%)
Forex
USD-INR
83.33 -0.11
(-0.13%)
EUR-INR
90.34 0.01
(0.02%)
GBP-INR
105.32 -0.01
(-0.01%)
JPY-INR
0.55 0.00
(-0.18%)

IPO Synopsis

  • YOU ARE HERE :
  • HOME breadcrum-arrow
  • IPO Synopsis

IPO

Windlas Biotech Ltd
Initial Public Offer of 8,729,023* equity shares of face value of Rs.5 each ("equity shares") of Windlas Biotech Limited ("company" Rs.455 per equity share) aggregating to Rs.401.54 Crores (the "offer") comprising a fresh issue of 3,586,956* equity shares aggregating to Rs.165 Crores (the "fresh issue") and an offer for sale of 5,142,067* equity shares, comprising of 1,136,000* equity shares aggregating to Rs.52.26* Crores by Vimla Windlass (the "individual selling shareholder") and 4,006,067* equity shares aggregating to Rs.184.28* Crores by Tano India Private Equity Fund II (the "investor selling shareholder", and collectively with the individual selling shareholder, the "selling shareholders", and such equity shares, the "offered shares") aggregating to Rs.236.54 Crores (the "offer for sale). The offer constitutes 40.05% of the post-offer paid-up equity share capital of the Company. The face value of equity shares is Rs.5 each. The offer price is Rs.460 per equity share and is 92 times the face value of the equity shares. *subject to finalisation of the basis of allotment.
Issue
Opens On Closes On
04-Aug-21 06-Aug-21
Money Payable On
Application Allotment
460.00 0.00
Minimum Application for shares in Nos : 30 Further Multiples of : 30
Cr Lead Managers to the Issue
Project Cost (.Cr) 165.00 DAM Capital Advisors Ltd
Project Financed through Current Offer (.Cr) 401.54  
Post Issue Equity Share Capital (.Cr) 10.90
Issue Price () 460.00
Projects
Purchase of Equipment required for (i) Capacity Expansion of the existing facility at the Dehradun Plant-IV and (II) Addition of Injectables Dosage Capability at the existing facility at Dehradun Plant - II
Funding Incremental Working Capital Requirements of the Company
Repayment/Prepayment of certain of the Borrowings
General Corporate Purposes
Promoted By
Ashok Kumar Windlass
Hitesh Windlass
Manoj Kumar Windlass
Listing At
BSE
NSE
Registrar to the Issue
No Data Available